NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Medicine & Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine & Law Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Affitech



Affitech to play key role in embryonal tumor pipeline project



October 13th, 2006

Affitech announced that it has been selected to participate in the new European Union E.E.T. Pipeline project to identify fully human therapeutic antibody candidates for Embryonal Tumors (ET) by using its unique antibody discovery platform.

The E.E.T. Pipeline project is a multidisciplinary consortium of leading European institutions and SME (Small and Medium Enterprise)s, which the E.U. is funding with EUR 4 million for developing new methods of diagnosis and treatment for ET. Such methods would be based on gene expression profiling of tumors and would include other post-genomic investigative technologies. The EU has taken this initiative since Embryonal Tumors are...


Source: Medicine & Law Weekly (2006-10-13)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login